AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio’s (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

AFRRI/NIAID partnership and validated animal models significantly derisk regulatory and commercial advancement of Company's lead candidatePositive momentum further positions Entolimod as a potential first and only treatment for GI-ARS, representing a multi-billion-dollar commercial opportunitySAN ANTONIO, June 25, 2026…

Read the full release →

News provided by PR Newswire.